Philina Lee
Director at DBVT
Board
About Philina Lee
Philina Lee, Ph.D., age 49, was appointed as an independent director of DBV Technologies on October 30, 2025, to replace Daniel Soland; she joined the Compensation Committee and her appointment is subject to shareholder ratification at the next annual meeting . She holds a B.S. in Biochemistry from the University of Alberta and a Ph.D. in Cell Biology from MIT, and most recently served as Chief Commercial Officer at Blueprint Medicines, having previously held senior roles across product strategy and marketing at Algeta, Sanofi, and Genzyme .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Blueprint Medicines | Chief Commercial Officer | Since April 2022 (per company disclosure) | Led commercialization, oversaw launch/growth of AYVAKIT |
| Blueprint Medicines | SVP, Head of Portfolio Strategy & Program Management | Jan 2021–Apr 2022 | Portfolio strategy and program oversight |
| Blueprint Medicines | Senior Director, New Product Strategy & Development; subsequent commercial roles | Aug 2014 onward | Strategy, operations, patient services, marketing, precision medicine field team |
| Algeta; Sanofi; Genzyme | Product strategy and marketing roles | Not specified | Progressive responsibility in commercial functions |
External Roles
| Organization | Role | Tenure | Committees |
|---|---|---|---|
| Fusion Pharmaceuticals | Director | 2021–2024 | Nomination & Governance; Research & Development |
Board Governance
- Appointment and roles: Appointed October 30, 2025 as independent director; member of Compensation Committee; appointment subject to shareholder ratification .
- Board size: With her addition, the Board comprised ten directors as of the announcement date .
- Independence and conflicts: No arrangements or understandings regarding her appointment; no family relationships with directors/executives; no direct or indirect material interest in transactions requiring Item 404(a) disclosure (related-party transactions) .
- Committee structure context: DBV maintains Audit, Compensation, and Nominating & Governance committees under charters aligned with Nasdaq, SEC, and French Commercial Code; committees are advisory under French law .
- Historical board attendance: In FY2024, each director attended at least 94% of Board meetings and 100% of committee meetings (context for engagement expectations; predates Lee’s appointment) .
- Securities and hedging policy: Company policy prohibits hedging by insiders (directors, officers, employees) .
Fixed Compensation
| Component | Amount/Term | Notes |
|---|---|---|
| Annual retainer (cash) | €100,000 per year | Non-employee director compensation policy |
| Compensation Committee member fee | €5,000 per year | For service on Compensation Committee |
| Directors’ total annual budget | €900,000 (increase proposed) | Intended to compensate a new Board member; all resolutions approved at the June 11, 2025 AGM |
Performance Compensation
| Item | Disclosure | Metrics/Terms |
|---|---|---|
| Performance-based director cash bonus | Not disclosed for non-employee directors | — |
| Director equity grants (RSUs/PSUs/Options) | 2024 director grants: no warrant awards; directors held prior non-employee warrants with subscription price ≥ fair market value on grant date | No 2024 grants; prior warrants outstanding as of Dec 31, 2024 |
Other Directorships & Interlocks
| Company | Relationship to DBV | Interlock/Conflict Indicator |
|---|---|---|
| Fusion Pharmaceuticals (prior) | No disclosed supplier/customer relationship with DBV | No interlocks or related-party exposure disclosed |
Expertise & Qualifications
- Education: B.S., Biochemistry (University of Alberta); Ph.D., Cell Biology (MIT) .
- Functional expertise: Commercial leadership in biopharma; portfolio strategy, product launches, patient services; led AYVAKIT commercialization at Blueprint Medicines .
- Governance experience: Prior public company board service (Fusion Pharmaceuticals) with roles on Nomination & Governance and R&D committees .
Equity Ownership
| Item | Status |
|---|---|
| DBVT beneficial ownership | Not listed in the April 15, 2025 beneficial ownership table (pre-appointment); table covers existing directors/executives at that date |
| Related-party transactions | None requiring Item 404(a) disclosure for Lee |
| Hedging/Pledging | Hedging prohibited by Company policy; no pledging disclosure for Lee |
Governance Assessment
- Independence and conflicts: Clear independence representation with no related-party transactions or appointment arrangements; supports investor confidence in governance integrity .
- Committee alignment: Placement on Compensation Committee leverages commercial and portfolio strategy expertise; oversight of pay practices is salient as DBV approaches potential commercialization .
- Shareholder signals: AGM approved all resolutions, including director compensation policy/budget increase to accommodate an additional director, indicating broad shareholder support for governance and compensation frameworks (context predating Lee’s appointment but relevant to Board capacity) .
- Data gaps and monitoring: Beneficial ownership and Section 16 holdings for Lee not yet enumerated in the May 2025 proxy due to timing; monitor upcoming proxy/Section 16 filings post-appointment for ownership alignment and any equity grants .
RED FLAGS: None disclosed—no related-party transactions, no family ties, and hedging prohibited. Keep watch for any future director equity award structures (e.g., warrant/option grants) and whether compensation remains predominantly fixed cash, which can dilute performance linkage if not balanced with long-term equity aligned to shareholder outcomes .